BronchUK: protocol for an observational cohort study and biobank in bronchiectasis
Author
De Soyza, AnthonyMawson, Philip
Hill, Adam T
Elborn, Stuart
Bradley, Judy M
Haworth, Charles S
Floto, R Andres
Wilson, Robert
Loebinger, Michael R
Carroll, Mary
Crichton, Megan
Chalmers, James D
Sullivan, Anita
Brown, Jeremy
Hurst, John R
Duckers, Jamie
Kelly, Martin
Steer, John
Gatheral, Tim
Walker, Paul P
Winstanley, Craig
McGuire, Alistair
Denning, David
McNally, Richard
Affiliation
Newcastle University; Royal Infirmary; University of Edinburgh; Queen's University; Royal Papworth Hospital; University of Cambridge; Imperial College London; University Hospital Southampton NHS Foundation Trust; University of Dundee; University Hospitals Birmingham NHS Foundation Trust; University College London; Cardiff and Vale University Health Board; Western Health and Social Care Trust; Northumbria Healthcare NHS Foundation Trust; University Hospitals of Morecambe Bay NHS Foundation Trust; Liverpool University Hospitals; University of Liverpool; London School of Economics; The University of ManchesterPublication date
2021-04-19
Metadata
Show full item recordAbstract
Bronchiectasis has been a largely overlooked disease area in respiratory medicine. This is reflected by a shortage of large-scale studies and lack of approved therapies, in turn leading to a variation of treatment across centres. BronchUK (Bronchiectasis Observational Cohort and Biobank UK) is a multicentre, prospective, observational cohort study working collaboratively with the European Multicentre Bronchiectasis Audit and Research Collaboration project. The inclusion criteria for patients entering the study are a clinical history consistent with bronchiectasis and computed tomography demonstrating bronchiectasis. Main exclusion criteria are 1) patients unable to provide informed consent, 2) bronchiectasis due to known cystic fibrosis or where bronchiectasis is not the main or co-dominant respiratory disease, 3) age <18 years, and 4) prior lung transplantation for bronchiectasis. The study is aligned to standard UK National Health Service (NHS) practice with an aim to recruit a minimum of 1500 patients from across at least nine secondary care centres. Patient data collected at baseline includes demographics, aetiology testing, comorbidities, lung function, radiology, treatments, microbiology and quality of life. Patients are followed up annually for a maximum of 5 years and, where able, blood and/or sputa samples are collected and stored in a central biobank. BronchUK aims to collect robust longitudinal data that can be used for analysis into current NHS practice and patient outcomes, and to become an integral resource to better inform future interventional studies in bronchiectasis.Citation
De Soyza A, Mawson P, Hill AT, Elborn S, Bradley JM, Haworth CS, Floto RA, Wilson R, Loebinger MR, Carroll M, Crichton M, Chalmers JD, Sullivan A, Brown J, Hurst JR, Duckers J, Kelly M, Steer J, Gatheral T, Walker PP, Winstanley C, McGuire A, Denning D, McNally R. BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Res. 2021 Apr 19;7(2):00775-2020. doi: 10.1183/23120541.00775-2020.Type
ArticleAdditional Links
https://publications.ersnet.org/content/erjorPMID
33898620Journal
ERJ Open ResearchPublisher
European Respiratory Societyae974a485f413a2113503eed53cd6c53
10.1183/23120541.00775-2020